Top

Published in:

01-11-2017 | Review Paper

Tumor angiogenesis and vascular normalization: alternative therapeutic targets

Authors: Claire Viallard, Bruno Larrivée

Published in: Angiogenesis | Issue 4/2017

Abstract

Tumor blood vessels are a key target for cancer therapeutic management. Tumor cells secrete high levels of pro-angiogenic factors which contribute to the creation of an abnormal vascular network characterized by disorganized, immature and permeable blood vessels, resulting in poorly perfused tumors. The hypoxic microenvironment created by impaired tumor perfusion can promote the selection of more invasive and aggressive tumor cells and can also impede the tumor-killing action of immune cells. Furthermore, abnormal tumor perfusion also reduces the diffusion of chemotherapeutic drugs and radiotherapy efficiency. To fight against this defective phenotype, the normalization of the tumor vasculature has emerged as a new therapeutic strategy. Vascular normalization, by restoring proper tumor perfusion and oxygenation, could limit tumor cell invasiveness and improve the effectiveness of anticancer treatments. In this review, we investigate the mechanisms involved in tumor angiogenesis and describe strategies used to achieve vascular normalization.

Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10:417–427. doi:10.1038/nrd3455 PubMedCrossRef

Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307. doi:10.1038/nature10144 PubMedPubMedCentralCrossRef

Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989. doi:10.1038/nm0901-987 PubMedCrossRef

Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62. doi:10.1126/science.1104819 PubMedCrossRef

Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26:605–622. doi:10.1016/j.ccell.2014.10.006 PubMedPubMedCentralCrossRef

Goel S, Duda DG, Xu L et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071–1121. doi:10.1152/physrev.00038.2010 PubMedPubMedCentralCrossRef

Gerhardt H, Golding M, Fruttiger M et al (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161:1163–1177. doi:10.1083/jcb.200302047 PubMedPubMedCentralCrossRef

Phng L-K, Gerhardt H (2009) Angiogenesis: a team effort coordinated by notch. Dev Cell 16:196–208. doi:10.1016/j.devcel.2009.01.015 PubMedCrossRef

Bray SJ (2016) Notch signalling in context. Nat Rev Mol Cell Biol. doi:10.1038/nrm.2016.94 PubMed

10.

Blanco R, Gerhardt H (2013) VEGF and Notch in Tip and Stalk Cell Selection. Cold Spring Harb Perspect Med. doi:10.1101/cshperspect.a006569 PubMedPubMedCentral

11.

Jakobsson L, Franco CA, Bentley K et al (2010) Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol 12:943–953. doi:10.1038/ncb2103 PubMedCrossRef

12.

Ferrara N, Gerber H-P, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676. doi:10.1038/nm0603-669 PubMedCrossRef

13.

Benedito R, Roca C, Sörensen I et al (2009) The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137:1124–1135. doi:10.1016/j.cell.2009.03.025 PubMedCrossRef

14.

Mattila PK, Lappalainen P (2008) Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol 9:446–454. doi:10.1038/nrm2406 PubMedCrossRef

15.

De Smet F, Segura I, De Bock K et al (2009) Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. Arterioscler Thromb Vasc Biol 29:639–649. doi:10.1161/ATVBAHA.109.185165 PubMedCrossRef

16.

Lamalice L, Boeuf FL, Huot J (2007) Endothelial cell migration during angiogenesis. Circ Res 100:782–794. doi:10.1161/01.RES.0000259593.07661.1e PubMedCrossRef

17.

Ridley AJ (2015) Rho GTPase signalling in cell migration. Curr Opin Cell Biol 36:103–112. doi:10.1016/j.ceb.2015.08.005 PubMedPubMedCentralCrossRef

18.

Phng L-K, Stanchi F, Gerhardt H (2013) Filopodia are dispensable for endothelial tip cell guidance. Development 140:4031–4040. doi:10.1242/dev.097352 PubMedCrossRef

19.

Larrivée B, Freitas C, Suchting S et al (2009) Guidance of vascular development: lessons from the nervous system. Circ Res 104:428–441. doi:10.1161/CIRCRESAHA.108.188144 PubMedCrossRef

20.

Larrivée B, Freitas C, Trombe M et al (2007) Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev 21:2433–2447. doi:10.1101/gad.437807 PubMedPubMedCentralCrossRef

21.

London NR, Smith MCP, Li DY (2009) Emerging mechanisms of vascular stabilization. J Thromb Haemost JTH 7(Suppl 1):57–60. doi:10.1111/j.1538-7836.2009.03421.x PubMedCrossRef

22.

Koch AW, Mathivet T, Larrivée B et al (2011) Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Dev Cell 20:33–46. doi:10.1016/j.devcel.2010.12.001 PubMedCrossRef

23.

Davis GE, Bayless KJ (2003) An integrin and Rho GTPase-dependent pinocytic vacuole mechanism controls capillary lumen formation in collagen and fibrin matrices. Microcirc NY N 10:27–44. doi:10.1038/sj.mn.7800175 CrossRef

24.

Davis GE, Koh W, Stratman AN (2007) Mechanisms controlling human endothelial lumen formation and tube assembly in three-dimensional extracellular matrices. Birth Defects Res Part C Embryo Today Rev 81:270–285. doi:10.1002/bdrc.20107 CrossRef

25.

Sacharidou A, Stratman AN, Davis GE (2012) Molecular mechanisms controlling vascular lumen formation in three-dimensional extracellular matrices. Cells Tissues Organs 195:122–143. doi:10.1159/000331410 PubMedCrossRef

26.

Strilić B, Kucera T, Eglinger J et al (2009) The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell 17:505–515. doi:10.1016/j.devcel.2009.08.011 PubMedCrossRef

27.

Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276–1312. doi:10.1101/gad.1653708 PubMedPubMedCentralCrossRef

28.

Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10:165–177. doi:10.1038/nrm2639 PubMedCrossRef

29.

Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10:575–585. doi:10.1038/nrc2894 PubMedCrossRef

30.

Lucke S, Levkau B (2010) Endothelial functions of sphingosine-1-phosphate. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 26:87–96. doi:10.1159/000315109 CrossRef

31.

Dejana E, Tournier-Lasserve E, Weinstein BM (2009) The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell 16:209–221. doi:10.1016/j.devcel.2009.01.004 PubMedCrossRef

32.

Privratsky JR, Newman PJ (2014) PECAM-1: regulator of endothelial junctional integrity. Cell Tissue Res 355:607–619. doi:10.1007/s00441-013-1779-3 PubMedPubMedCentralCrossRef

33.

Wallez Y, Huber P (2008) Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta BBA: Biomembr 1778:794–809. doi:10.1016/j.bbamem.2007.09.003 CrossRef

34.

Bergers G, Song S (2005) The role of pericytes in blood-vessel formation and maintenance. Neuro-Oncol 7:452–464. doi:10.1215/S1152851705000232 PubMedPubMedCentralCrossRef

35.

Morikawa S, Baluk P, Kaidoh T et al (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160:985–1000. doi:10.1016/S0002-9440(10)64920-6 PubMedPubMedCentralCrossRef

36.

Abramsson A, Lindblom P, Betsholtz C (2003) Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112:1142–1151. doi:10.1172/JCI200318549 PubMedPubMedCentralCrossRef

37.

Greenberg JI, Shields DJ, Barillas SG et al (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456:809–813. doi:10.1038/nature07424 PubMedPubMedCentralCrossRef

38.

Ribatti D, Crivellato E (2012) Mast cells, angiogenesis, and tumour growth. Biochim Biophys Acta 1822:2–8. doi:10.1016/j.bbadis.2010.11.010 PubMedCrossRef

39.

Guo M, Breslin JW, Wu MH et al (2008) VE-cadherin and beta-catenin binding dynamics during histamine-induced endothelial hyperpermeability. Am J Physiol Cell Physiol 294:C977–C984. doi:10.1152/ajpcell.90607.2007 PubMedPubMedCentralCrossRef

40.

Beckers CML, van Hinsbergh VWM, van Nieuw Amerongen GP (2010) Driving Rho GTPase activity in endothelial cells regulates barrier integrity. Thromb Haemost 103:40–55. doi:10.1160/TH09-06-0403 PubMedCrossRef

41.

Baluk P, Morikawa S, Haskell A et al (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163:1801–1815. doi:10.1016/S0002-9440(10)63540-7 PubMedPubMedCentralCrossRef

42.

Inai T, Mancuso M, Hashizume H et al (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35–52. doi:10.1016/S0002-9440(10)63273-7 PubMedPubMedCentralCrossRef

43.

Jain RK, Martin JD, Stylianopoulos T (2014) The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng 16:321–346. doi:10.1146/annurev-bioeng-071813-105259 PubMedPubMedCentralCrossRef

44.

Reymond N, d’Água BB, Ridley AJ (2013) Crossing the endothelial barrier during metastasis. Nat Rev Cancer 13:858–870. doi:10.1038/nrc3628 PubMedCrossRef

45.

Kim BG, Gao M-Q, Kang S et al (2017) Mechanical compression induces VEGFA overexpression in breast cancer via DNMT3A-dependent miR-9 downregulation. Cell Death Dis 8:e2646. doi:10.1038/cddis.2017.73 PubMedPubMedCentralCrossRef

46.

Heldin C-H, Rubin K, Pietras K, Östman A (2004) High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer 4:806–813. doi:10.1038/nrc1456 PubMedCrossRef

47.

Giaccia AJ, Simon MC, Johnson R (2004) The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev 18:2183–2194. doi:10.1101/gad.1243304 PubMedPubMedCentralCrossRef

48.

Mazzone M, Dettori D, Leite de Oliveira R et al (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136:839–851. doi:10.1016/j.cell.2009.01.020 PubMedPubMedCentralCrossRef

49.

Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ et al (2009) HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 9:1084–1101PubMedCrossRef

50.

Darby IA, Hewitson TD (2016) Hypoxia in tissue repair and fibrosis. Cell Tissue Res 365:553–562. doi:10.1007/s00441-016-2461-3 PubMedCrossRef

51.

Masoud GN, Li W (2015) HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B 5:378–389. doi:10.1016/j.apsb.2015.05.007 PubMedPubMedCentralCrossRef

52.

Bullen JW, Tchernyshyov I, Holewinski RJ et al (2016) Protein kinase A-dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1. Sci Signal 9:ra56. doi:10.1126/scisignal.aaf0583 PubMedPubMedCentralCrossRef

53.

Larcher F, Franco M, Bolontrade M et al (2003) Modulation of the angiogenesis response through Ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis. Mol Carcinog 37:83–90. doi:10.1002/mc.10126 PubMedCrossRef

54.

Rak J, Yu JL (2004) Oncogenes and tumor angiogenesis: the question of vascular “supply” and vascular “demand”. Semin Cancer Biol 14:93–104. doi:10.1016/j.semcancer.2003.09.014 PubMedCrossRef

55.

Arbiser JL, Moses MA, Fernandez CA et al (1997) Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 94:861–866PubMedPubMedCentralCrossRef

56.

Govindarajan B, Bai X, Cohen C et al (2003) Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 278:9790–9795. doi:10.1074/jbc.M212929200 PubMedCrossRef

57.

Sofia Vala I, Martins LR, Imaizumi N et al (2010) Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS ONE 5:e11222. doi:10.1371/journal.pone.0011222 PubMedPubMedCentralCrossRef

58.

Hillen F, Griffioen AW (2007) Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 26:489–502. doi:10.1007/s10555-007-9094-7 PubMedPubMedCentralCrossRef

59.

Ribatti D, Djonov V (2012) Intussusceptive microvascular growth in tumors. Cancer Lett 316:126–131. doi:10.1016/j.canlet.2011.10.040 PubMedCrossRef

60.

Paku S, Dezso K, Bugyik E et al (2011) A new mechanism for pillar formation during tumor-induced intussusceptive angiogenesis: inverse sprouting. Am J Pathol 179:1573–1585. doi:10.1016/j.ajpath.2011.05.033 PubMedPubMedCentralCrossRef

61.

Ribatti D, Nico B, Floris C et al (2005) Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma. Oncol Rep 14:81–84PubMed

62.

Maniotis AJ, Folberg R, Hess A et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155:739–752. doi:10.1016/S0002-9440(10)65173-5 PubMedPubMedCentralCrossRef

63.

Paulis YWJ, Soetekouw PMMB, Verheul HMW et al (2010) Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta 1806:18–28. doi:10.1016/j.bbcan.2010.01.001 PubMed

64.

Chang YS, di Tomaso E, McDonald DM et al (2000) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97:14608–14613. doi:10.1073/pnas.97.26.14608 PubMedPubMedCentralCrossRef

65.

Ruf W, Seftor EA, Petrovan RJ et al (2003) Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 63:5381–5389PubMed

66.

Yang JP, Liao YD, Mai DM et al (2016) Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis. Angiogenesis 19:191–200. doi:10.1007/s10456-016-9500-2 PubMedCrossRef

67.

Qian C-N (2013) Hijacking the vasculature in ccRCC–co-option, remodelling and angiogenesis. Nat Rev Urol 10:300–304. doi:10.1038/nrurol.2013.26 PubMedCrossRef

68.

Lyden D, Hattori K, Dias S et al (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201. doi:10.1038/nm1101-1194 PubMedCrossRef

69.

Rafii S, Meeus S, Dias S et al (2002) Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol 13:61–67. doi:10.1006/scdb.2001.0285 PubMedCrossRef

70.

Patenaude A, Parker J, Karsan A (2010) Involvement of endothelial progenitor cells in tumor vascularization. Microvasc Res 79:217–223. doi:10.1016/j.mvr.2010.01.007 PubMedCrossRef

71.

Gao D, Nolan DJ, Mellick AS et al (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319:195–198. doi:10.1126/science.1150224 PubMedCrossRef

72.

Peters BA, Diaz LA, Polyak K et al (2005) Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11:261–262. doi:10.1038/nm1200 PubMedCrossRef

73.

Larrivée B, Karsan A (2007) Involvement of marrow-derived endothelial cells in vascularization. Handb Exp Pharmacol. doi:10.1007/978-3-540-68976-8_5 PubMed

74.

Wickersheim A, Kerber M, de Miguel LS et al (2009) Endothelial progenitor cells do not contribute to tumor endothelium in primary and metastatic tumors. Int J Cancer 125:1771–1777. doi:10.1002/ijc.24605 PubMedCrossRef

75.

Purhonen S, Palm J, Rossi D et al (2008) Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci USA 105:6620–6625. doi:10.1073/pnas.0710516105 PubMedPubMedCentralCrossRef

76.

Larrivée B, Niessen K, Pollet I et al (2005) Minimal contribution of marrow-derived endothelial precursors to tumor vasculature. J Immunol Baltim Md 175:2890–2899

77.

Machein MR, Renninger S, de Lima-Hahn E, Plate KH (2003) Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol Zur Switz 13:582–597CrossRef

78.

Zentilin L, Tafuro S, Zacchigna S et al (2006) Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. Blood 107:3546–3554. doi:10.1182/blood-2005-08-3215 PubMedCrossRef

79.

Ricci-Vitiani L, Pallini R, Biffoni M et al (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468:824–828. doi:10.1038/nature09557 PubMedCrossRef

80.

Kaur S, Bajwa P (2014) A “tête-à tête” between cancer stem cells and endothelial progenitor cells in tumor angiogenesis. Clin Trans Oncol 16:115–121. doi:10.1007/s12094-013-1103-4 CrossRef

81.

Orth M, Lauber K, Niyazi M et al (2014) Current concepts in clinical radiation oncology. Radiat Environ Biophys 53:1–29. doi:10.1007/s00411-013-0497-2 PubMedCrossRef

82.

Busk M, Horsman MR (2013) Relevance of hypoxia in radiation oncology: pathophysiology, tumor biology and implications for treatment. Q J Nucl Med Mol Imag 57:219–234

83.

Cosse J-P, Michiels C (2008) Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 8:790–797PubMedCrossRef

84.

Luk CK, Veinot-Drebot L, Tjan E, Tannock IF (1990) Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J Natl Cancer Inst 82:684–692PubMedCrossRef

85.

Young SD, Hill RP (1990) Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. J Natl Cancer Inst 82:371–380PubMedCrossRef

86.

Sanna K, Rofstad EK (1994) Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 58:258–262PubMedCrossRef

87.

Viallard C, Chezal J-M, Mishellany F et al (2016) Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy. Oncotarget 7:12927–12936. doi:10.18632/oncotarget.7340 PubMedPubMedCentralCrossRef

88.

Klein M, Lotem M, Peretz T et al (2013) Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J Skin Cancer 2013:828329. doi:10.1155/2013/828329 PubMedPubMedCentralCrossRef

89.

Huang Y, Goel S, Duda DG et al (2013) Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73:2943–2948. doi:10.1158/0008-5472.CAN-12-4354 PubMedPubMedCentralCrossRef

90.

Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949. doi:10.1038/nm1093 PubMedCrossRef

91.

Movahedi K, Laoui D, Gysemans C et al (2010) Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70:5728–5739. doi:10.1158/0008-5472.CAN-09-4672 PubMedCrossRef

92.

Corzo CA, Condamine T, Lu L et al (2010) HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207:2439–2453. doi:10.1084/jem.20100587 PubMedPubMedCentralCrossRef

93.

Leung DW, Cachianes G, Kuang WJ et al (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309PubMedCrossRef

94.

Senger DR, Galli SJ, Dvorak AM et al (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983–985PubMedCrossRef

95.

Crawford Y, Ferrara N (2009) VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 335:261–269. doi:10.1007/s00441-008-0675-8 PubMedCrossRef

96.

Ohtsu A, Shah MA, Van Cutsem E et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968–3976. doi:10.1200/JCO.2011.36.2236 PubMedCrossRef

97.

Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227–1234. doi:10.1200/JCO.2007.14.5466 PubMedCrossRef

98.

Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676. doi:10.1056/NEJMoa072113 PubMedCrossRef

99.

Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134. doi:10.1056/NEJMoa060655 PubMedCrossRef

100.

Jayson GC, Kerbel R, Ellis LM, Harris AL (2016) Antiangiogenic therapy in oncology: current status and future directions. Lancet Lond Engl 388:518–529. doi:10.1016/S0140-6736(15)01088-0 CrossRef

101.

Fan F, Samuel S, Gaur P et al (2011) Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer 104:1270–1277. doi:10.1038/bjc.2011.81 PubMedPubMedCentralCrossRef

102.

Widakowich C, de Castro G, de Azambuja E et al (2007) Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12:1443–1455. doi:10.1634/theoncologist.12-12-1443 PubMedCrossRef

103.

Tolaney SM, Boucher Y, Duda DG et al (2015) Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci USA 112:14325–14330. doi:10.1073/pnas.1518808112 PubMedPubMedCentralCrossRef

104.

Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553–563. doi:10.1016/j.ccr.2004.10.011 PubMed

105.

Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95. doi:10.1016/j.ccr.2006.11.021 PubMedPubMedCentralCrossRef

106.

Graeber TG, Osmanian C, Jacks T et al (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88–91. doi:10.1038/379088a0 PubMedCrossRef

107.

Ebos JML, Kerbel RS (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8:210–221. doi:10.1038/nrclinonc.2011.21 PubMedPubMedCentralCrossRef

108.

Huang Y, Yuan J, Righi E et al (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 109:17561–17566. doi:10.1073/pnas.1215397109 PubMedPubMedCentralCrossRef

109.

Martin JD, Fukumura D, Duda DG et al (2016) Reengineering the tumor microenvironment to alleviate hypoxia and overcome cancer heterogeneity. Cold Spring Harb Perspect Med. doi:10.1101/cshperspect.a027094

110.

Chen B-B, Lu Y-S, Lin C-H et al (2016) A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. BMC Cancer 16:466. doi:10.1186/s12885-016-2494-8 PubMedPubMedCentralCrossRef

111.

Lin A, Hahn SM (2012) Hypoxia imaging markers and applications for radiation treatment planning. Semin Nucl Med 42:343–352. doi:10.1053/j.semnuclmed.2012.04.002 PubMedCrossRef

112.

Becker S, Bohn P, Bouyeure-Petit A-C et al (2015) Bevacizumab enhances efficiency of radiotherapy in a lung adenocarcinoma rodent model: role of αvβ3 imaging in determining optimal window. Nucl Med Biol 42:923–930. doi:10.1016/j.nucmedbio.2015.08.002 PubMedCrossRef

113.

Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79:27–38. doi:10.1159/000314980 PubMedCrossRef

114.

Nalluri SR, Chu D, Keresztes R et al (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277–2285. doi:10.1001/jama.2008.656 PubMedCrossRef

115.

Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592–603. doi:10.1038/nrc2442 PubMedPubMedCentralCrossRef

116.

Xian X, Håkansson J, Ståhlberg A et al (2006) Pericytes limit tumor cell metastasis. J Clin Invest 116:642–651. doi:10.1172/JCI25705 PubMedPubMedCentralCrossRef

117.

García-Román J, Zentella-Dehesa A (2013) Vascular permeability changes involved in tumor metastasis. Cancer Lett 335:259–269. doi:10.1016/j.canlet.2013.03.005 PubMedCrossRef

118.

Thomas M, Augustin HG (2009) The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 12:125–137. doi:10.1007/s10456-009-9147-3 PubMedCrossRef

119.

Witzenbichler B, Maisonpierre PC, Jones P et al (1998) Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 273:18514–18521PubMedCrossRef

120.

Jones N, Master Z, Jones J et al (1999) Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem 274:30896–30905PubMedCrossRef

121.

Hayes AJ, Huang WQ, Mallah J et al (1999) Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res 58:224–237. doi:10.1006/mvre.1999.2179 PubMedCrossRef

122.

Teichert-Kuliszewska K, Maisonpierre PC, Jones N et al (2001) Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 49:659–670PubMedCrossRef

123.

Kwak HJ, So JN, Lee SJ et al (1999) Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 448:249–253PubMedCrossRef

124.

Kim I, Kim JH, Moon SO et al (2000) Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 19:4549–4552. doi:10.1038/sj.onc.1203800 PubMedCrossRef

125.

Holash J, Wiegand SJ, Yancopoulos GD (1999) New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18:5356–5362. doi:10.1038/sj.onc.1203035 PubMedCrossRef

126.

Nasarre P, Thomas M, Kruse K et al (2009) Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 69:1324–1333. doi:10.1158/0008-5472.CAN-08-3030 PubMedPubMedCentralCrossRef

127.

Leow CC, Coffman K, Inigo I et al (2012) MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 40:1321–1330. doi:10.3892/ijo.2012.1366 PubMed

128.

Holopainen T, Saharinen P, D’Amico G et al (2012) Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst 104:461–475. doi:10.1093/jnci/djs009 PubMedPubMedCentralCrossRef

129.

Peterson TE, Kirkpatrick ND, Huang Y et al (2016) Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci USA 113:4470–4475. doi:10.1073/pnas.1525349113 PubMedPubMedCentralCrossRef

130.

Kloepper J, Riedemann L, Amoozgar Z et al (2016) Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci USA 113:4476–4481. doi:10.1073/pnas.1525360113 PubMedPubMedCentralCrossRef

131.

Coxon A, Bready J, Min H et al (2010) Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 9:2641–2651. doi:10.1158/1535-7163.MCT-10-0213 PubMedPubMedCentralCrossRef

132.

Mita AC, Takimoto CH, Mita M et al (2010) Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 16:3044–3056. doi:10.1158/1078-0432.CCR-09-3368 PubMedCrossRef

133.

Monk BJ, Poveda A, Vergote I et al (2016) Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol 143:27–34. doi:10.1016/j.ygyno.2016.07.112 PubMedCrossRef

134.

Goel S, Gupta N, Walcott BP et al (2013) Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst 105:1188–1201. doi:10.1093/jnci/djt164 PubMedPubMedCentralCrossRef

135.

Park J-S, Kim I-K, Han S et al (2016) Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell 30:953–967. doi:10.1016/j.ccell.2016.10.018 PubMedCrossRef

136.

Chakroborty D, Sarkar C, Yu H et al (2011) Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci USA 108:20730–20735. doi:10.1073/pnas.1108696108 PubMedPubMedCentralCrossRef

137.

Al-Husein B, Goc A, Somanath PR (2013) Suppression of interactions between prostate tumor cell integrin αvβ3 and endothelial ICAM-1 by simvastatin inhibits prostate cancer micrometastasis. J Cell Physiol 228:2139. doi:10.1002/jcp.24381 PubMedPubMedCentralCrossRef

138.

Heldin C-H (2013) Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal CCS 11:97. doi:10.1186/1478-811X-11-97 PubMedCrossRef

139.

Huang J, Soffer SZ, Kim ES et al (2004) Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res MCR 2:36–42PubMed

140.

Bergers G, Song S, Meyer-Morse N et al (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287–1295. doi:10.1172/JCI200317929 PubMedPubMedCentralCrossRef

141.

Erber R, Thurnher A, Katsen AD et al (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338–340. doi:10.1096/fj.03-0271fje PubMed

142.

Timke C, Zieher H, Roth A et al (2008) Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 14:2210–2219. doi:10.1158/1078-0432.CCR-07-1893 PubMedCrossRef

143.

Hawthorne T, Giot L, Blake L et al (2008) A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther 46:236–244PubMedCrossRef

144.

Jayson GC, Parker GJM, Mullamitha S et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23:973–981. doi:10.1200/JCO.2005.01.032 PubMedCrossRef

145.

Shen J, Vil MD, Prewett M et al (2009) Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia NY N 11:594–604CrossRef

146.

Falcon BL, Pietras K, Chou J et al (2011) Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. Am J Pathol 178:2920. doi:10.1016/j.ajpath.2011.02.019 PubMedPubMedCentralCrossRef

147.

Lu C, Shahzad MMK, Moreno-Smith M et al (2010) Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 9:176PubMedPubMedCentralCrossRef

148.

Davis DW, Takamori R, Raut CP et al (2005) Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res 11:678–689PubMedCrossRef

149.

Nisancioglu MH, Betsholtz C, Genové G (2010) The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res 70:5109–5115. doi:10.1158/0008-5472.CAN-09-4245 PubMedCrossRef

150.

Kim J, de Sampaio PC, Lundy DM et al (2016) Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy. JCI Insight 1:e90733. doi:10.1172/jci.insight.90733 PubMedPubMedCentralCrossRef

151.

McCarty MF, Somcio RJ, Stoeltzing O et al (2007) Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 117:2114. doi:10.1172/JCI31334 PubMedPubMedCentralCrossRef

152.

Reis M, Czupalla CJ, Ziegler N et al (2012) Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med 209:1611. doi:10.1084/jem.20111580 PubMedPubMedCentralCrossRef

153.

Liu J, Liao S, Huang Y et al (2011) PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res 17:3638–3648. doi:10.1158/1078-0432.CCR-10-2456 PubMedPubMedCentralCrossRef

154.

Lamouille S, Mallet C, Feige J-J, Bailly S (2002) Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 100:4495–4501. doi:10.1182/blood.V100.13.4495 PubMedCrossRef

155.

Suzuki Y, Ohga N, Morishita Y et al (2010) BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J Cell Sci 123:1684–1692. doi:10.1242/jcs.061556 PubMedCrossRef

156.

Valdimarsdottir G, Goumans M-J, Rosendahl A et al (2002) Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 106:2263–2270PubMedCrossRef

157.

Itoh F, Itoh S, Goumans M-J et al (2004) Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells. EMBO J 23:541–551. doi:10.1038/sj.emboj.7600065 PubMedPubMedCentralCrossRef

158.

Larrivée B, Prahst C, Gordon E et al (2012) ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev Cell 22:489–500. doi:10.1016/j.devcel.2012.02.005 PubMedPubMedCentralCrossRef

159.

Rostama B, Turner JE, Seavey GT et al (2015) DLL4/Notch1 and BMP9 interdependent signaling induces human endothelial cell quiescence via P27KIP1 and thrombospondin-1. Arterioscler Thromb Vasc Biol 35:2626–2637. doi:10.1161/ATVBAHA.115.306541 PubMedPubMedCentralCrossRef

160.

Scharpfenecker M, van Dinther M, Liu Z et al (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120:964–972. doi:10.1242/jcs.002949 PubMedCrossRef

161.

David L, Mallet C, Keramidas M et al (2008) Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res 102:914–922. doi:10.1161/CIRCRESAHA.107.165530 PubMedPubMedCentralCrossRef

162.

Gupta S, Gill D, Pal SK, Agarwal N (2015) Activin receptor inhibitors–dalantercept. Curr Oncol Rep 17:14. doi:10.1007/s11912-015-0441-5 PubMedCrossRef

163.

Mitchell D, Pobre EG, Mulivor AW et al (2010) ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 9:379–388. doi:10.1158/1535-7163.MCT-09-0650 PubMedCrossRef

164.

Makker V, Filiaci VL, Chen L-M et al (2015) Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N. Gynecol Oncol 138:24–29. doi:10.1016/j.ygyno.2015.04.006 PubMedPubMedCentralCrossRef

165.

Wang X, Solban N, Khanna P et al (2016) Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget. doi:10.18632/oncotarget.9621

166.

van Meeteren LA, Thorikay M, Bergqvist S et al (2012) Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem 287:18551–18561. doi:10.1074/jbc.M111.338103 PubMedPubMedCentralCrossRef

167.

Necchi A, Giannatempo P, Mariani L et al (2014) PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Invest New Drugs 32:555–560. doi:10.1007/s10637-014-0074-9 PubMedCrossRef

168.

Wilson CW, Ye W (2014) Regulation of vascular endothelial junction stability and remodeling through Rap1-Rasip1 signaling. Cell Adhes Migr 8:76–83CrossRef

169.

Maharjan S, Kim K, Agrawal V et al (2013) Sac-1004, a novel vascular leakage blocker, enhances endothelial barrier through the cAMP/Rac/cortactin pathway. Biochem Biophys Res Commun 435:420–427. doi:10.1016/j.bbrc.2013.04.104 PubMedCrossRef

170.

Agrawal V, Maharjan S, Kim K et al (2014) Direct endothelial junction restoration results in significant tumor vascular normalization and metastasis inhibition in mice. Oncotarget 5:2761–2777PubMedPubMedCentralCrossRef

171.

Lee K, Agrawal V, Kim K et al (2014) Combined effect of vascular-leakage-blocker Sac-1004 and antiangiogenic drug sunitinib on tumor angiogenesis. Biochem Biophys Res Commun 450:1320–1326. doi:10.1016/j.bbrc.2014.06.139 PubMedCrossRef

172.

Loboda A, Jozkowicz A, Dulak J (2010) HIF-1 and HIF-2 transcription factors–similar but not identical. Mol Cells 29:435–442. doi:10.1007/s10059-010-0067-2 PubMedCrossRef

173.

Skuli N, Liu L, Runge A et al (2009) Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood 114:469–477. doi:10.1182/blood-2008-12-193581 PubMedPubMedCentralCrossRef

174.

Le Bras A, Lionneton F, Mattot V et al (2007) HIF-2alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites. Oncogene 26:7480–7489. doi:10.1038/sj.onc.1210566 PubMedCrossRef

175.

Kleibeuker EA, Fokas E, Allen PD et al (2016) Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. Oncotarget. doi:10.18632/oncotarget.12814

176.

Zhang B, Shi W, Jiang T et al (2016) Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy. Oncotarget 7:62607–62618. doi:10.18632/oncotarget.11546 PubMedPubMedCentralCrossRef

177.

Maes H, Kuchnio A, Peric A et al (2014) Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 26:190–206. doi:10.1016/j.ccr.2014.06.025 PubMedCrossRef

178.

Liu F, Wang P, Jiang X et al (2008) Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 99:2055–2061. doi:10.1111/j.1349-7006.2008.00905.x PubMed

179.

Daskalow K, Rohwer N, Raskopf E et al (2010) Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. J Mol Med Berl Ger 88:817–827. doi:10.1007/s00109-010-0623-4 CrossRef

180.

Choi SH, Shin HW, Park JY et al (2010) Effects of the knockdown of hypoxia inducible factor-1α expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines. Korean J Hepatol 16:280–287. doi:10.3350/kjhep.2010.16.3.280 PubMedPubMedCentralCrossRef

181.

Choi SH, Kwon O-J, Park JY et al (2014) Inhibition of tumour angiogenesis and growth by small hairpin HIF-1α and IL-8 in hepatocellular carcinoma. Liver Int 34:632–642. doi:10.1111/liv.12375 PubMedCrossRef

Title: Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Authors: Claire Viallard
Bruno Larrivée
Publication date: 01-11-2017
Publisher: Springer Netherlands
Published in: Angiogenesis / Issue 4/2017
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI: https://doi.org/10.1007/s10456-017-9562-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Tumor angiogenesis and vascular normalization: alternative therapeutic targets

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1

History and conceptual developments in vascular biology and angiogenesis research: a personal view

Low levels of physiological interstitial flow eliminate morphogen gradients and guide angiogenesis

Pharmacological intervention of MKL/SRF signaling by CCG-1423 impedes endothelial cell migration and angiogenesis

Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall

Optical clearing and fluorescence deep-tissue imaging for 3D quantitative analysis of the brain tumor microenvironment

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page